Introduction
In today’s fast-paced clinical trial landscape, accelerating study start-up while ensuring compliance with regulatory and scientific requirements is crucial. Sponsors are always seeking more efficient ways of working to help them bring drugs to market faster. At study start up there are many ways clinical trial design can be optimised to avoid delays. One way is through access to an electronic clinical outcome assessment (eCOA) library. In this blog we explain what an eCOA library is, its benefits and the requirements for building one. We also share the experiences of an eCOA provider who shortened study start up timelines by creating an eCOA library.
What is an eCOA library?
An eCOA library contains pre-built and pre-approved versions of electronic COAs and their accompanying translations. The library is stored on a central, secure platform for authorised users, which enables the reuse of these materials across studies. This shared access of pre-approved eCOAs leads to substantially simplified workflows and reduced timelines and costs.
Who can build an eCOA library?
An eCOA library can be built by:
- An eCOA platform provider who will make the eCOA library available to their clients
- A sponsor who has their own eCOA platform for use on their own studies
- A sponsor who selects an eCOA platform provider to host an eCOA library for that sponsor’s use only
Benefits of an eCOA Library
An eCOA library allows sponsors to use their resources more efficiently. Timelines are reduced because there is no need to rebuild eCOAs in the platform. Another important advantage of an eCOA library is the cost savings aspect. The original English does not need to undergo repeated screenshot reviews. Access to an eCOA library can also expedite regulatory submissions as the eCOA library is maintained with up-to-date copyright holders’ requirements and approved screenshots. Several steps in eCOA implementation are removed with eCOA library access, as illustrated in the graphic.
How an eCOA provider saved five weeks during study start up
An eCOA provider was under pressure to reduce study start up timelines. They sought support from ICON to implement the eCOAs for sponsor use. The eCOA provider had developed several COAs for 10 studies over the previous 12 months. These eCOAs were distributed on provisioned smartphones. The main COAs were the Hospital Anxiety and Depression Scale questionnaire (HADS), a trial-specific version of the Zarit Burden Interview (ZBI-22) for a sponsor and Neuropathic Pain Symptom Inventory (NPSI).
Mapi Research Trust (MRT) proposed to build an eCOA library to certify and maintain the HADS, trial-specific sponsor version of the ZBI-22 and the NPSI for future use via the eCOA library. This eCOA provider has a sponsor that was re-using a trial specific version of the ZBI-22 and with permission they were able to include this in the eCOA library.
MRT also identified 10 additional COAs and included these in their eCOA library. MRT maintains a list of COAs certified per study with each eCOA provider. Using this list, they identified other COAs that are most frequently implemented by eCOA providers and can be leveraged for eCOA library use.
By creating and maintaining an eCOA library of their 13 COAs, the eCOA provider saved approximately five weeks of screenshot reviews for each COA. The bank of eCOAs in US English were readily available to sponsors for regulatory submissions
How an eCOA library can reduce your study start up timelines
Considerations for building your eCOA library
Many COAs are copyrighted instruments and maintaining their integrity is essential. When migrating from paper version into an electronic format, steps must be taken to protect the COA from unintended changes.
To protect the integrity of an approved library version of a COA, the eCOA platform provider must consider the following areas:
- Limit access to the eCOA library to authorised users
- Protect approved eCOA library version from changes to content and design, even when added to a study
- Maintain an audit trail of all changes: what changes were made, by whom, and when
- Version control of source English and translations
- Maintain updated versions: eCOA libraries must be kept up to date with the current industry best practices and the developer or copyright holders’ requirements for electronic use. It is important that your eCOA library includes a maintenance service where you are informed of any changes and required updates.
Because of the additional work involved in creating and maintaining an eCOA library many companies partner with ICON to develop their libraries in collaboration with the eCOA platform of their choice. By choosing a reliable eCOA library solution, sponsors can focus on other elements of study start up while their service providers maintain their library.
ICON’s eCOA Library service
ICON’s eCOA Library service has access to over 800 COAs through MRT.
There are four components of the ICON eCOA Library service:
- Licensing: COAs distributed by MRT are copyrighted, appropriate licensing permissions are put in place for eCOA Library use.
- Screenshots review and certification of source English version: MRT reviews the electronic versions of each COA added to an eCOA Library.
- Screenshot review of translations: ICON Language Services reviews the translated electronic versions of each COA added to an eCOA library. The reviews are performed at both initial set-up and at re-use on a study level.
- Maintenance: MRT ensures the integrity of the eCOAs in line with the developers’/copyright holders’ requirements and eCOA best practice. MRT informs the eCOA provider of any relevant updates required to the library version of the COA.
Conclusion
Having access to an up-to-date eCOA library can save study start up time from lengthy screenshot reviews. One eCOA provider who worked with ICON was able to shorten their sponsors’ screenshot review step timeline by approximately five weeks. An eCOA library allows sponsors to access up-to-date, copyrighted COAs, while expediting the regulatory submissions process. Before developing an eCOA library, ensure that the copyrighted COAs’ integrity is protected and that they are updated following industry’s best practice.
CTA: Contact us to learn more about eCOA technology and eCOA Library service.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel